NAGIOS: RODERIC FUNCIONANDO

PMS2:a potential prognostic protein marker in oral squamous cell carcinoma

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

PMS2:a potential prognostic protein marker in oral squamous cell carcinoma

dc.contributor.author	Decker, Jordana Medeiros Lira	es
dc.contributor.author	Filho, Osias Vieira de Oliveira	es
dc.contributor.author	Freitas, Milena Oliveira	es
dc.contributor.author	Silva-Fernandes, Isabelle Joyce de Lima	es
dc.contributor.author	Sousa-Dantas, Thinali	es
dc.contributor.author	Campêlo, Clarissa Sales de Paula	es
dc.contributor.author	Socorro-Saldanha-Cunha, Maria do Perpétuo	es
dc.contributor.author	Silva, Paulo-Goberlânio-de Barros	es
dc.contributor.author	Sousa, Fabrício Bitu	es
dc.date.accessioned	2023-06-16T08:36:41Z
dc.date.available	2023-06-16T08:36:41Z
dc.date.issued	2021	es
dc.identifier.citation	Decker, JM., Filho, OV., Freitas, MO., Silva-Fernandes, IJ., Dantas, TS., Campêlo, CS., Cunha, Md., Silva, PG., & Sousa, FB. (2021). PMS2: a potential prognostic protein marker in oral squamous cell carcinoma. En Medicina Oral Patología Oral y Cirugia Bucal (pp. e451-e458). Medicina Oral, S.L. https://doi.org/10.4317/medoral.24303	es
dc.identifier.uri	https://hdl.handle.net/10550/88045
dc.description.abstract	An increase in oral squamous cell carcinoma (OSCC) cases was observed despite the reduction in exposure to classic risk factors. Although the exact cause of this trend remains unknown, epigenetic factors could be contributing to an increased occurrence of these tumors. This study aims to assess the influence of PMS2 protein immunoexpression on the prognosis of patients with OSCC. This study comprised 76 cases of OSCC treated between 2011 and 2016. Immunohistochemical staining for PMS2 was performed. For evaluation, 10 fields per histological section were photographed at a 400x magnification and positively-stained cells were counted with Image J. Mann-Whitney and Kruskal-Wallis tests were used to compare the immunolabeling pattern with the clinical-pathological and prognostic characteristics. Survival analysis was performed with Chi-square, Long-Rank Mantel-Cox and Cox regression tests (p<0.05). An overexpression of PMS2 was observed in N0/1 tumors and in oral cancers found in unusual locations. In patients ?60 years of age, high levels of PMS2 ( >60%; p=0.041) were associated with low survival (p=0.029). In multivariate analysis, surgery combined with chemotherapy (p=0.030) and high PMS2 immunoexpression (p=0.042) significantly increased the risk of death for ?60 years old patients. The findings of this study indicate that PMS2 can be a potential prognostic protein marker in OSCC patients 60 years of age and younger.	es
dc.subject	periodontal disease	es
dc.subject	periodontitis	es
dc.subject	prostate cancer	es
dc.subject	meta-analysis	es
dc.title	PMS2:a potential prognostic protein marker in oral squamous cell carcinoma	es
dc.type	journal article	es_ES
dc.subject.unesco	UNESCO:CIENCIAS MÉDICAS	es
dc.identifier.doi	10.4317/medoral.24303	es
dc.type.hasVersion	VoR	es_ES
dc.identifier.url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254887/